Biocon, Mylan NV launch Semglee in Australia | | Udaipur News | Udaipur Latest News | udaipur local news । Udaipur Updates
Home / BUSINESS / Biocon, Mylan NV launch Semglee in Australia

Biocon, Mylan NV launch Semglee in Australia

Biocon and Mylan N.V. have launched Semglee (insulin glargine solution for injection 100 IU/mL in a 3mL pre-filled pen), the first insulin glargine biosimilar in Australia available on the Pharmaceutical Benefits Scheme (PBS).

Insulin glargine is a long-acting basal insulin analogue, given once daily to help control the blood sugar levels of those with diabetes. It is indicated for the treatment of type 1 diabetes mellitus in adults, adolescents and children aged six years and above and type 2 diabetes mellitus in adults.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient’s worldwide.

Please share this news